

Demographics, Disease Characteristics, And Patient-Reported Outcomes Among Patients with Psoriasis Who Initiated Guselkumab in Corevitas' Psoriasis Registry

Jessica A. Walsh¹, Kristina Callis Duffin¹, Abby S. Van Voorhees², Soumya D. Chakravarty^{3,4}, Timothy Fitzgerald^{3*}, Amanda Teeple³, Katelyn Rowland³, Jonathan Uy⁵, Robert R. McLean⁶, Wendi Malley⁶, Angel Cronin⁶, Joseph F. Merola⁷

¹University of Utah, Salt Lake City, UT, USA; ²Eastern Virginia Medical School, Norfolk, VA, USA; ³Janssen Scientific Affairs LLC, Horsham, PA, USA; ⁴Drexel University College of Medicine, Philadelphia, PA, USA; ⁵Janssen Global Services LLC, Horsham, PA, USA; ⁶CorEvitas LLC, Waltham, MA, USA; ⁷Harvard Medical School, Brigham and Women's Hospital, Boston, MA, USA.

***Corresponding Author:**

Timothy Fitzgerald
Director, Immunology, Real World Value & Evidence
Janssen Scientific Affairs LLC
Horsham, PA 19044, USA
Email: TFitzg11@its.jnj.com
Telephone: (267) 678-3875

Table S1: Baseline demographics and disease characteristics of patients with psoriasis and concomitant rheumatologist-confirmed psoriatic arthritis who initiated guselkumab in CorEvitas' Psoriasis Registry by prior biologic use

Characteristics ^a	Prior biologic use ^b (n)		Standardized difference ^c
	Biologic-naïve (n = 10)	Biologic-experienced (n = 103)	
Age (years), mean (SD)	55.9 (10.6)	51.7 (13.4)	0.35
Female, n (%)	5 (50.0)	59 (57.3)	0.15
White, n (%)	7 (70.0)	90 (87.4)	0.43
Private health insurance, n (%)	10 (100.0)	83 (80.6)	0.69
Some college or more, n (%)	8 (80.0)	74 (71.8)	0.19
Employed full time n, (%)	6 (60.0)	56 (54.4)	0.11
Current smoker, n/N _i (%)	2/9 (22.2)	18/103 (17.5)	0.12
Body weight (kg), mean (SD)	100.8 (21.9)	98.9 (24.4)	0.09
BMI >30 kg/m ² , n (%)	6 (60.0)	69 (67.0)	0.15
History of comorbidities, n (%)			
Cancer ^d	0 (0.0)	7 (6.8)	0.38
Serious infections	0 (0.0)	10 (9.7)	0.46
Cardiovascular disease ^e	1 (10.0)	5 (4.9)	0.20
Hypertension	5 (50.0)	26 (25.2)	0.53
Hyperlipidemia	1 (10.0)	14 (13.6)	0.11
Diabetes mellitus	1 (10.0)	8 (7.8)	0.08
Crohn's disease	0 (0.0)	1 (1.0)	0.14
Ulcerative colitis	0 (0.0)	1 (1.0)	0.14
Depression	1 (10.0)	13 (12.6)	0.08
Anxiety	2 (20.0)	15 (14.6)	0.14
BSA (%), mean (SD)	14.5 (10.6)	12.4 (16.4)	0.15
PASI (score: 0-72), mean (SD)	10.9 (6.2)	8.3 (8.8)	0.34
IGA, mean (SD)	3.2 (0.6)	2.7 (1.1)	0.55
Psoriasis morphology			
Scalp	6 (60.0)	46 (44.7)	0.31
Nail	2 (20.0)	25 (24.3)	0.10
Palmoplantar	2 (20.0)	27 (26.2)	0.15
Genital	4 (40.0)	11 (10.7)	0.72
Psoriasis duration (years), mean (SD)	23.0 (18.6)	19.5 (13.3)	0.22
PsA duration (years), mean (SD)	n = 10 15.3 (17.8)	n = 94 10.9 (9.3)	0.31
PEST score ≥3, n (%)	5/10 (50.0)	66/102 (64.7)	0.30
Concomitant therapy, n (%)			
Systemic therapy ^f	1 (10.0)	27 (26.2)	0.43
Topical agents	7 (70.0)	42 (40.8)	0.62

^a Item non-response was <1% for all cells, unless denominator is reported.

^b Biologic medications included adalimumab, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, secukinumab, and ustekinumab.

^c Meaningful differences (standardized difference >0.10) are bolded.

^d Cancer includes lymphoma, lung, breast, skin (basal cell, squamous cell, melanoma), and any other cancers.

^e Cardiovascular disease includes baseline history of any of the following: cardiac revascularization procedure, ventricular arrhythmia, cardiac arrest, myocardial infarction, acute coronary syndrome, unstable angina, coronary artery disease, and congestive heart failure; cerebrovascular disease includes baseline history of any of the following: stroke, TIA, peripheral vascular disease, peripheral arterial disease.

^f Systemic therapy includes biologics listed above and the non-biologics apremilast, cyclosporine, acitretin, and methotrexate.

Abbreviations: BMI = body mass index; BSA = body surface area; IGA = Investigator's Global Assessment; PASI = Psoriasis Area Severity Index; PEST = Psoriasis Epidemiology Screening Tool; PsA = psoriatic arthritis; SD = standard deviation; TIA = transient ischemic attack.

Table S2: Baseline patient-reported outcome measures for patients with psoriasis and concomitant rheumatologist-confirmed psoriatic arthritis who initiated guselkumab in CorEvitas' Psoriasis Registry by prior biologic use

Characteristics ^a	Prior biologic use ^b (n)		Standardized difference ^c
	Biologic-naïve (n = 10)	Biologic-experienced (n = 103)	
Overall patient-reported outcomes, mean (SD)			
Overall itch/pruritus (VAS 0-100)	77.0 (21.2)	52.4 (35.4)	0.84
Overall fatigue (VAS 0-100)	53.0 (25.7)	48.9 (33.3)	0.14
Overall skin pain (VAS 0-100)	50.0 (36.5)	42.2 (35.8)	0.22
PGA (VAS 0-100)	62.9 (19.1)	50.4 (29.9)	0.50
PsA patient-reported outcomes, n	n = 10	n = 99	
Joint pain due to PsA (VAS 0-100), mean (SD)	55.5 (31.4)	51.2 (32.1)	0.13
Wellness as a result of PsA (VAS 0-100), mean (SD)	56.0 (28.2)	46.5 (31.4)	0.32
WPAI, mean (SD)			
Currently employed, n (%)	7 (70.0) n = 6	65 (63.1) n = 61	0.15
% of work hours missed due to PsO	6.7 (15.1) n = 6	6.8 (17.8) n = 61	0.00
% of impairment while working due to PsO	25.0 (21.2) n = 6	19.2 (26.7) n = 60	0.24
% of work hours affected by PsO	28.6 (25.9) n = 10	21.3 (29.0) n = 101	0.27
% of daily activities impaired by PsO	37.0 (25.3)	29.2 (31.0)	0.28
DLQI (score: 0-30), mean (SD)	n = 10 11.0 (4.7)	n = 101 9.2 (7.2)	0.30
DLQI "effect on life", n (%)	n = 10	n = 101	0.80
0-1: none	0 (0.0)	15 (14.9)	
2-5: small	1 (10.0)	22 (21.8)	
6-10: moderate	5 (50.0)	25 (24.8)	
11-20: very large	3 (30.0)	29 (28.7)	
21-30: extremely large	1 (10.0)	10 (9.9)	
EQ-5D VAS (0-100), mean (SD)	67.5 (14.6)	63.6 (22.7)	0.21
ED-5D-3L categorical domains, n (%) ^d			
Walking	5 (50.0)	50 (49.5)	0.01
Self-care	1 (10.0)	21 (21.0)	0.31
Usual activities	7 (70.0)	50 (49.5)	0.43
Pain and discomfort	7 (70.0)	79 (78.2)	0.19
Anxiety and depression	3 (30.0)	40 (40.0)	0.21
Problems with sleeping	2 (20.0)	30 (29.4)	0.22

^a Not all patients provided responses to all patient-reported outcomes; item non-response was <2% for all cells, unless denominator is reported. Note that the three WPAI summary scores related to working are applicable only to those who are currently employed.

^b Biologic medications included adalimumab, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, secukinumab, and ustekinumab.

^c Meaningful differences (standardized difference >0.10) are bolded.

^d Percentage of patients reporting at least some problem.

Abbreviations: DLQI = Dermatology Life Quality Index; EQ-5D = EuroQoL-5 dimensions; EQ-5D-3L = EuroQoL-5 dimensions, 3 levels; PsA = psoriatic arthritis; PsO = psoriasis; SD = standard deviation; VAS = visual analog scale.